Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
Lee, S Lewanski, C Counsell, N Ottensmeier, C Bates, A Patel, N Wadsworth, C Ngai, Y Hackshaw, A Faivre-Finn, Corinne
Lee, S
Lewanski, C
Counsell, N
Ottensmeier, C
Bates, A
Patel, N
Wadsworth, C
Ngai, Y
Hackshaw, A
Faivre-Finn, Corinne
Citations
Altmetric:
Abstract
Median survival of non-small cell lung cancer (NSCLC) patients with brain metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) followed by maintenance erlotinib in patients with untreated brain metastases, given the potential radiosensitizing properties of erlotinib and its direct effect on brain metastases and systemic activity.
Description
Date
2014-07
Publisher
Collections
Keywords
Type
Article
Citation
Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases. 2014, 106 (7): J Natl Cancer Inst